Pharmacokinetics of escalating doses of intravenous repinotan in healthy male volunteers

Clinical Drug Investigation

Volumn 25, Issue 2, 2005, Pages 115-123

  Heinig, Roland ^a   Böttcher, Michael F ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; REPINOTAN; SEROTONIN 1A AGONIST;

ARTICLE; BODY WEIGHT; CAUCASIAN; CLINICAL TRIAL; CORRELATION ANALYSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MALE; NEUROTOXICITY; NORMAL HUMAN; PALLOR; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE; SWEATING; VOMITING;

EID: 14644397916     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525020-00004     Document Type: Article

References (9)

1. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002; 33: 2123-36
2. Lees KR. Neuroprotection is unlikely to be effective in humans using current trial designs: an opposing view. Stroke 2002; 33: 308-9
3. Stroke Therapy Academic Industry Roundtable II (STAIR II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001; 32: 1598-606
4. De Vry J, Dietrich H, Glaser T, et al. BAY x-3702. Drugs of the Future 1997; 22: 341-9
5. 1A receptor agonist BAY x 3702 in a rat model of permanent focal cerebral ischemia and traumatic brain injury [abstract]. Soc Neurosci 1997; 23: 1923
6. Teal P, on behalf of the BRAINS Study Group. BRAINS, a phase II study of the neuroprotectant, BAY x 3702 in patients with ischemic stroke [abstract]. Cerebrovasc Dis 1998; 8 Suppl. 4: 20
7. Fleckenstein L, Roche L, Sundaresan PR, et al. Ascending-dose safety and tolerability study of BAY x 3702 in healthy elderly males and females [abstract]. Clin Pharmacol Ther 1998; 63: 190
8. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/ sparteine metabolism: clinical aspects. Pharmacol Ther 1990; 46: 377-94
9. Bertilsson L, Dahl ML. Polymorphic drug oxidation, relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 5: 200-23